Champions Oncology (CSBR) Cash & Equivalents (2010 - 2026)

Champions Oncology (CSBR) has 17 years of Cash & Equivalents data on file, last reported at $4.4 million in Q3 2026.

• On a quarterly basis, Cash & Equivalents fell 57.38% year-over-year to $4.4 million in Q3 2026; TTM through Jul 2026 was $4.4 million, a 57.38% decrease from a year earlier, with the FY2026 full-year figure at $4.9 million, down 50.21% from the prior year.
• Cash & Equivalents for Q3 2026 stood at $4.4 million, down from $4.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $11.6 million in Q1 2023 and bottomed at $2.6 million in Q2 2024.
• Historically, Cash & Equivalents has averaged $6.8 million across 5 years, with a median of $7.1 million in 2026.
• The widest annual swing landed in 2024, when Cash & Equivalents slumped 74.13%; it then soared 273.76% in 2025.
• Year by year, Cash & Equivalents stood at $10.8 million in 2022, then slumped by 49.08% to $5.5 million in 2023, then plunged by 50.05% to $2.8 million in 2024, then jumped by 209.22% to $8.5 million in 2025, then slumped by 48.33% to $4.4 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $4.4 million in Q3 2026, $4.9 million in Q2 2026, and $7.1 million in Q1 2026.